
UK and Germany to Jointly Develop New Strike Weapon
The move follows a commitment the countries made to develop new weapons in a bilateral defense pact known as the Trinity House Agreement, signed last October.
The weapons project will be jointly announced by British Defense Secretary John Healey and his German counterpart, Boris Pistorius, in Berlin later on Thursday.
The new precision deep strike capability will be among the most advanced systems ever designed by the UK to safeguard the British public and reinforce NATO deterrence, while boosting the UK and European defense sectors, the UK Ministry of Defense
Healy and Pistorius will also discuss a joint procurement program for Sting Ray torpedoes for P-8 Poseidon maritime patrol and reconnaissance aircraft, to improve both countries' ability to counter underwater threats.
British Defense Secretary John Healey said: 'The UK and Germany have never been closer, and the Trinity House Agreement is already making a positive impact on our security and economy. This partnership is helping us make defense an engine for growth—creating jobs, boosting skills, and driving investment across the UK and Germany.
Related Stories
5/14/2025
5/14/2025
'In a more dangerous world, NATO and European allies stand united. Together with Germany, we're leading the way in supporting Ukraine, defending NATO's eastern flank, and jointly investing in next-generation capabilities.'
Britain was a founding member of NATO, joining the alliance in 1949, while West Germany joined in 1955 during the Cold War, with East Germany becoming part of the alliance after German reunification in 1990.
The nations are currently Europe's two biggest economies.
Further details on the project's timeline or budget have not yet been released.
Since the Trinity House Agreement was signed in October, German crews have joined RAF personnel in two flights on UK P-8 Poseidon aircraft, London's Defense Ministry said.
The ministers will meet again on Friday alongside their Polish, Italian, and French counterparts in a meeting of the European Group of Five Defense ministers in Rome.
The quintet last met in Paris in March of this year, where they discussed support for Ukraine and Europe's place in NATO.
The move by Berlin and London comes amid a continent-wide recalibration of defense policy and expenditure after U.S. President Donald Trump made clear he expects Europe to take more responsibility for its own security.
Germany's parliament approved in March plans for a
The fiscal plan includes 500 billion euros (about $571 billion) for a special fund for infrastructure and plans to largely remove defense spending from domestic rules that cap borrowing.
Earlier this week, French President Emmanuel Macron said he was 'ready to open a discussion' about
February saw German Chancellor Friedrich Merz call for a discussion on 'nuclear sharing' with France, while in March, Polish Prime Minister Donald Tusk said Poland was 'talking seriously with the French' about the 'idea of a nuclear umbrella over Europe.'
Plans moved forward on May 9 when Paris and Warsaw
Chris Summers and Reuters contributed to this report.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNBC
17 minutes ago
- CNBC
Sweden's Volvo Cars switches gears in the U.S. as tariffs bite
Sweden-based automaker Volvo Cars plans to change tack in the U.S. as Washington's trade tariffs take their toll. Volvo Cars, which is owned by China's Geely Holding, on Thursday reported that second-quarter operating profit excluding items affecting comparability fell to 2.9 billion Swedish kronor ($297.83 million), down from 8 billion during the same time last year. Second-quarter revenue dropped to 93.5 billion kronor, compared to 101.5 billion kronor over the same period in 2024. Volvo Cars, which is widely considered as one of the most exposed European carmakers to U.S. tariffs, said the result reflects an ongoing challenging environment for the automotive industry. The company said it was also impacted by a previously announced one-off non-cash impairment charge of 11.4 billion kronor. The second-quarter earnings come shortly after Volvo Cars launched plans to add its best-selling XC60 sports utility vehicle to the production line of its U.S. car plant in Ridgeville outside Charleston in South Carolina. Production of the XC60, which has been the firm's best-selling model globally for years, is scheduled to start at the factory in late 2026. At the same time, Volvo Cars has started pulling sedans and station wagons from its U.S. portfolio amid waning interest, Reuters reported Thursday. It comes as U.S. tariffs of 27.5% on European-made cars and 100% on EVs imported from China have forced automakers to review their product strategies. Volvo Cars CEO Håkan Samuelsson said the company would "definitely not" pull out of the U.S. market, where it has been present for 70 years. "What we are doing is first of all, we want to fill our factory we have in South Carolina. It should be the strategic asset it was intended to be. So, we have to utilize it more," Samuelsson told CNBC's "Europe Early Edition" on Thursday. "Second, of course, now with the tariffs, it is very natural to bring in a [car model with] big-selling volume. We are bringing in the XC60 SUV," he added.
Yahoo
an hour ago
- Yahoo
European Market Highlights: High Leads 3 Promising Penny Stocks
The European market has recently experienced a mixed performance, with the pan-European STOXX Europe 600 Index ending slightly higher amid hopes for more trade deals, although gains were curbed by tariff concerns. As investors navigate these shifting conditions, they often seek opportunities in various segments of the market. Penny stocks, though an outdated term, still represent a niche area where smaller or newer companies can offer growth potential when backed by strong financial health. This article will explore three promising penny stocks that may provide hidden value and long-term potential despite their modest price points. Top 10 Penny Stocks In Europe Name Share Price Market Cap Financial Health Rating Lucisano Media Group (BIT:LMG) €0.95 €14.11M ★★★★☆☆ Maps (BIT:MAPS) €3.39 €45.03M ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.60 SEK269.95M ★★★★★★ IAMBA Arad (BVB:FERO) RON0.49 RON16.57M ★★★★★★ Cellularline (BIT:CELL) €2.89 €60.95M ★★★★★☆ Fondia Oyj (HLSE:FONDIA) €5.00 €18.7M ★★★★★★ Abak (WSE:ABK) PLN4.38 PLN11.8M ★★★★★★ Bredband2 i Skandinavien (OM:BRE2) SEK2.41 SEK2.31B ★★★★☆☆ Deceuninck (ENXTBR:DECB) €2.135 €294.77M ★★★★★★ Netgem (ENXTPA:ALNTG) €0.984 €33.18M ★★★★★★ Click here to see the full list of 332 stocks from our European Penny Stocks screener. Let's dive into some prime choices out of the screener. High Simply Wall St Financial Health Rating: ★★★★★★ Overview: High Co. SA offers consumer engagement chain solutions in France, Belgium, and Spain with a market cap of €85.29 million. Operations: The company generates €146.38 million in revenue from its advertising segment. Market Cap: €85.29M High Co. SA, with a market cap of €85.29 million, generates €146.38 million in revenue from its advertising segment across France, Belgium, and Spain. The company maintains high-quality earnings without significant shareholder dilution over the past year and has reduced its debt to equity ratio to 0% over five years. Despite stable weekly volatility and well-covered interest payments by EBIT (57.2x), it faces challenges with negative earnings growth (-27.4%) last year and declining profit margins (5.3% from 7.3%). While trading below fair value estimates, future earnings are forecasted to decline by an average of 15.3% annually over three years. Get an in-depth perspective on High's performance by reading our balance sheet health report here. Review our growth performance report to gain insights into High's future. Isofol Medical Simply Wall St Financial Health Rating: ★★★★★★ Overview: Isofol Medical AB (publ) is a clinical stage biotech company with a market cap of SEK161.52 million. Operations: Isofol Medical AB (publ) has not reported any revenue segments. Market Cap: SEK161.52M Isofol Medical AB, a clinical-stage biotech firm with a market cap of SEK161.52 million, is pre-revenue and unprofitable but has been reducing losses by 30.7% annually over the past five years. The company remains debt-free and its short-term assets surpass both short- and long-term liabilities, providing some financial stability. Recent strategic moves include a private placement raising SEK4.99 million and ongoing clinical trials for arfolitixorin in metastatic colorectal cancer treatment, with FDA engagement indicating potential U.S. expansion plans. However, Isofol's management team lacks experience, contributing to higher-than-average stock volatility in Sweden. Click here to discover the nuances of Isofol Medical with our detailed analytical financial health report. Gain insights into Isofol Medical's future direction by reviewing our growth report. Xbrane Biopharma Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Xbrane Biopharma AB is a biotechnology company focused on the development, manufacture, and sale of biosimilars, with a market cap of SEK388.26 million. Operations: The company generates revenue from its biosimilar development segment, amounting to SEK277.89 million. Market Cap: SEK388.26M Xbrane Biopharma, with a market cap of SEK388.26 million, is focused on biosimilars and has shown significant revenue growth, reporting SEK93.24 million in Q1 2025 compared to SEK14.07 million the previous year. Despite being unprofitable and having high debt levels (net debt to equity at 57.8%), its seasoned management team and strategic partnerships are promising for future developments. The recent collaboration with OneSource aims to enhance global supply capabilities and regulatory approvals for its lead candidate Ximluci, which is under U.S. FDA review after gaining European market authorization in 2023. Take a closer look at Xbrane Biopharma's potential here in our financial health report. Understand Xbrane Biopharma's earnings outlook by examining our growth report. Turning Ideas Into Actions Reveal the 332 hidden gems among our European Penny Stocks screener with a single click here. Ready For A Different Approach? Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:HCO OM:ISOFOL and OM:XBRANE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
an hour ago
- Yahoo
Chord Energy Corporation (CHRD): A Bull Case Theory
We came across a bullish thesis on Chord Energy Corporation on Stock Analysis Compilation's Substack. In this article, we will summarize the bulls' thesis on CHRD. Chord Energy Corporation's share was trading at $106.72 as of July 14th. CHRD's trailing P/E was 7.1 according to Yahoo Finance. An industrial plant producing natural gas compression equipment, illuminated by night. Chord Energy is a low-cost exploration and production (E&P) company operating in the Williston Basin, presenting a compelling investment opportunity due to its strong balance sheet, consistent free cash flow, and significant shareholder returns. Following the sharp decline in oil prices in April, Chord's stock traded below the firm's net asset value based on its proven reserves, creating a valuation mismatch. In 2024, Chord generated $2.35 billion in EBITDA and $1 billion in free cash flow, underscoring its operational efficiency and robust cash generation. With only $800 million in debt, most of which matures in 2033, the company has significant financial flexibility, enabling it to continue rewarding shareholders through dividends and share repurchases. Since 2021, Chord has returned $56 per share in dividends—more than half its current share price—demonstrating a clear commitment to capital return. The firm's combination of disciplined capital management, low-cost reserves, and minimal near-term debt obligations makes its equity highly attractive, especially with a market cap of just around $5 billion. The company's ability to generate substantial free cash flow even in a volatile commodity environment supports the continuation of shareholder returns and underpins a long-term value opportunity. With the stock trading below the intrinsic value of its reserves and the firm maintaining high free cash flow yields, Chord stands out as a mispriced E&P business. Investors benefit not only from near-term cash returns but also from the long-term optionality in oil prices, positioning Chord Energy as a high-quality, undervalued play in the energy sector. Previously, we covered a on Civitas Resources, Inc. by mbacandidate1 in January 2025, which highlighted the company's debt-funded growth strategy, undervaluation relative to peers, and high shareholder yield. The company's stock price has depreciated by approximately 39.44% since our coverage. This is because the thesis didn't play out as expected. The thesis still stands as upside remains if operations stabilize. Stock Analysis Compilation shares a similar view on Chord Energy but emphasizes a stronger balance sheet and more consistent capital returns. Chord Energy Corporation is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 48 hedge fund portfolios held CHRD at the end of the first quarter which was 56 in the previous quarter. While we acknowledge the potential of CHRD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data